Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.48 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15619214 | 0.90 | RAB9A (0.51) | KCNQ3KCNQ2KCNQ5L3MBTL1CYP1A2 | |
| SCHEMBL14783706 | 0.89 | NPC1 (0.51) | KCNQ3KCNQ2KCNQ5CYP1A2CYP3A4 | |
| SCHEMBL15689199 | 0.89 | NPC1 (0.51) | KCNQ3KCNQ2KCNQ5CYP1A2CYP3A4 | |
| SCHEMBL29590370 | 0.89 | NPC1 (0.51) | KCNQ3KCNQ2KCNQ5CYP1A2CYP3A4 | |
| SCHEMBL14784220 | 0.88 | BRAF (0.62) | KCNQ3KCNQ2KCNQ5RAB9AMEN1 | |
| SCHEMBL14783303 | 0.87 | RAB9A (0.48) | L3MBTL1CYP1A2NPC1RAB9AMEN1 | |
| SCHEMBL29590810 | 0.87 | RAB9A (0.48) | L3MBTL1CYP1A2NPC1RAB9AMEN1 | |
| SCHEMBL28773423 | 0.86 | BRAF (0.49) | KCNQ3KCNQ2NPC1RAB9AMEN1 | |
| SCHEMBL14783358 | 0.85 | L3MBTL1 (0.54) | KCNQ3KCNQ2KCNQ5L3MBTL1CYP1A2 | |
| SCHEMBL29590707 | 0.85 | L3MBTL1 (0.54) | KCNQ3KCNQ2KCNQ5L3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065932-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-09-04 | — | — | US | claimed |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-05-17 | — | — | US | claimed |
| EP-2755657-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-11-29 | — | — | EP | claimed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | claimed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065932-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885KCNQ5 863/4885 |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885KCNQ5 863/4885 |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1219/4885KCNQ2 604/4885KCNQ5 863/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885KCNQ5 769/4885 |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885KCNQ5 769/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | KCNQ3 1107/4885KCNQ2 529/4885KCNQ5 769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.